Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 1.319
Filter
1.
Oncol Res ; 32(6): 1011-1019, 2024.
Article in English | MEDLINE | ID: mdl-38827323

ABSTRACT

This review aimed to describe the inculpation of microRNAs (miRNAs) in thyroid cancer (TC) and its subtypes, mainly medullary thyroid carcinoma (MTC), and to outline web-based tools and databases for bioinformatics analysis of miRNAs in TC. Additionally, the capacity of miRNAs to serve as therapeutic targets and biomarkers in TC management will be discussed. This review is based on a literature search of relevant articles on the role of miRNAs in TC and its subtypes, mainly MTC. Additionally, web-based tools and databases for bioinformatics analysis of miRNAs in TC were identified and described. MiRNAs can perform as oncomiRs or antioncoges, relying on the target mRNAs they regulate. MiRNA replacement therapy using miRNA mimics or antimiRs that aim to suppress the function of certain miRNAs can be applied to correct miRNAs aberrantly expressed in diseases, particularly in cancer. MiRNAs are involved in the modulation of fundamental pathways related to cancer, resembling cell cycle checkpoints and DNA repair pathways. MiRNAs are also rather stable and can reliably be detected in different types of biological materials, rendering them favorable diagnosis and prognosis biomarkers as well. MiRNAs have emerged as promising tools for evaluating medical outcomes in TC and as possible therapeutic targets. The contribution of miRNAs in thyroid cancer, particularly MTC, is an active area of research, and the utility of web applications and databases for the biological data analysis of miRNAs in TC is becoming increasingly important.


Subject(s)
Biomarkers, Tumor , Carcinoma, Neuroendocrine , Computational Biology , MicroRNAs , Thyroid Neoplasms , Humans , Thyroid Neoplasms/genetics , Thyroid Neoplasms/diagnosis , Thyroid Neoplasms/therapy , Thyroid Neoplasms/pathology , MicroRNAs/genetics , Biomarkers, Tumor/genetics , Carcinoma, Neuroendocrine/genetics , Carcinoma, Neuroendocrine/pathology , Carcinoma, Neuroendocrine/diagnosis , Prognosis , Computational Biology/methods , Gene Expression Regulation, Neoplastic , Internet , Molecular Targeted Therapy
2.
PLoS One ; 19(6): e0303440, 2024.
Article in English | MEDLINE | ID: mdl-38837985

ABSTRACT

Neuroendocrine carcinoma (NEC) is a rare yet potentially perilous neoplasm. The objective of this study was to develop prognostic models for the survival of NEC patients in the genitourinary system and subsequently validate these models. A total of 7125 neuroendocrine neoplasm (NEN) patients were extracted. Comparison of survival in patients with different types of NEN before and after propensity score-matching (PSM). A total of 3057 patients with NEC, whose information was complete, were extracted. The NEC influencing factors were chosen through the utilization of the least absolute shrinkage and selection operator regression model (LASSO) and the Fine & Gary model (FGM). Furthermore, nomograms were built. To validate the accuracy of the prediction, the efficiency was verified using bootstrap self-sampling techniques and receiver operating characteristic curves. LASSO and FGM were utilized to construct three models. Confirmation of validation was achieved by conducting analyses of the area under the curve and decision curve. Moreover, the FGS (DSS analysis using FGM) model produced higher net benefits. To maximize the advantages for patients, the FGS model disregarded the influence of additional occurrences. Patients are expected to experience advantages in terms of treatment options and survival assessment through the utilization of these models.


Subject(s)
Carcinoma, Neuroendocrine , Nomograms , Humans , Carcinoma, Neuroendocrine/mortality , Carcinoma, Neuroendocrine/pathology , Carcinoma, Neuroendocrine/diagnosis , Male , Female , Middle Aged , Retrospective Studies , Aged , Urogenital Neoplasms/mortality , Urogenital Neoplasms/diagnosis , Urogenital Neoplasms/pathology , Prognosis , Adult , ROC Curve
3.
Zhonghua Yi Xue Za Zhi ; 104(20): 1825-1830, 2024 May 28.
Article in Chinese | MEDLINE | ID: mdl-38782750

ABSTRACT

Objectives: To analyze the clinical characteristics and prognosis of medullary thyroid microcarcinoma (MTMC). Methods: A case series studies. The clinical data of patients with medullary thyroid carcinoma (MTC) diagnosed by postoperative pathology and with complete follow-up data who were initially treated in Tianjin Medical University Cancer Hospital from January 2013 to December 2019 were retrospectively analyzed. There were a total of 170 cases, including 70 males and 100 females, aged (49.7±12.3) years old. Among them, there were 61 patients with MTMC. They were divided into group A (with a maximum tumor idameter of ≤0.5 cm, n=13) and group B (with a maximum tumor diameter >0.5~≤1.0 cm, n=48) based on whether the maximum diameter of the tumor was >0.5 cm. Analysis was conducted on their pathological results and prognosis. Results: Among the MTC, MTMC accounted for 26.4% (61/231) with 26 males and 35 females aged Mï¼»Q1,Q3ï¼½51.0 (41.0, 59.0) years. Among the MTMC patients, 57.4% (35/61) were in stage Ⅰ, 16.4% (10/61) were in stage Ⅲ, and 26.2% (16/61) were in stage Ⅳ. For MTMC with a maximum diameter of≤0.5 cm and a maximum diameter of >0.5-≤1.0 cm, there was no statistically significant difference between the two groups in terms of gender, age, mixed cancer, invasion of glandular lobes, multifocal, central lymph node metastasis, lateral neck lymph node metastasis rate and other pathological characteristics(both P>0.05). In terms of prognosis, the recurrence free survival time of MTMC patients was 83.1 (68.0, 97.0) months. Among them, structural tumor recurrence occurred in 5 patients (8.2%) after surgery, and 1 patient (1.6%) died. The expected 5-year and 10-year survival rates were 93.4% and 89.0%, respectively. There was no statistically significant difference in recurrence free survival time among MTMC patients, MTC patients with a maximum diameter of >1.0-≤2.0 cm, and MTC patients with a maximum diameter of >2.0 cm (all P>0.05). Conclusion: MTMC has strong invasiveness, and although the prognosis of most MTMCs is relatively good, the risk of long-term recurrence and death is still high.


Subject(s)
Carcinoma, Neuroendocrine , Thyroid Neoplasms , Humans , Male , Female , Thyroid Neoplasms/pathology , Middle Aged , Prognosis , Retrospective Studies , Carcinoma, Neuroendocrine/pathology , Carcinoma, Neuroendocrine/diagnosis , Lymphatic Metastasis , Adult , Neoplasm Recurrence, Local
4.
Zhonghua Zhong Liu Za Zhi ; 46(5): 449-456, 2024 May 23.
Article in Chinese | MEDLINE | ID: mdl-38742358

ABSTRACT

Objectives: To investigate the proportion of different histological types and CT enhanced imaging features of primary middle mediastinal lesions in order to improve the understanding of these tumors and the accuracy of preoperative diagnosis. Methods: Retrospective analysis was conducted on 84 patients with primary middle mediastinal lesions and clear histological classifications diagnosed and treated at the Cancer Hospital, Chinese Academy of Medical Sciences from January 2012 to December 2022. Clinical, imaging, and pathological data were collected and classified according to tumor histological classifications. CT imaging manifestations such as tumor location, size, morphology, edge, boundary, internal components, enhancement characteristics, and surrounding tissue invasion were evaluated and recorded. Results: The histological types of the primary middle mediastinal lesions from the 84 patients included mesenchymal tumors, anterior intestinal cysts, giant lymph node hyperplasia, substernal goiter, neuroendocrine carcinoma, lymphohematopoietic system tumors, and mesothelioma, accounting for 28.6%, 27.4%, 14.3%, 3.6%, 11.9%, 9.5%, and 4.8%, respectively. Mesenchymal tumors included peripheral nerve sheath tumors, vascular tumors, adipogenic tumors, solitary fibrous tumors, and synovial sarcoma, accounting for 54.2%, 20.8%, 12.5%, 8.3%, and 4.2%, respectively. The above tumors had diverse imaging manifestations and specific imaging features. Mature fat were found in 3 cases of liposarcoma; Calcification was observed in 2 cases of thyroid nodules and 7 cases of giant lymph node hyperplasia; Enhanced scanning showed significant enhancement in 2 cases of solitary fibrous tumors, 3 cases of thyroid nodules, and 11 cases of giant lymph node hyperplasia; Mediastinal large lymph nodes was observed in 6 cases of lymphoma and 3 cases of mesothelioma; High invasiveness was observed in 4 cases of mesothelioma and 9 cases of neuroendocrine carcinoma. Conclusion: Mediastinal tumors have low incidence rate and rich histological types, and their imaging manifestations are diverse. Preoperative differential diagnosis can be made according to their specific imaging characteristics.


Subject(s)
Mediastinal Neoplasms , Tomography, X-Ray Computed , Humans , Mediastinal Neoplasms/diagnostic imaging , Mediastinal Neoplasms/pathology , Retrospective Studies , Carcinoma, Neuroendocrine/diagnostic imaging , Carcinoma, Neuroendocrine/pathology , Carcinoma, Neuroendocrine/diagnosis , Lymph Nodes/pathology , Lymph Nodes/diagnostic imaging , Mediastinum/diagnostic imaging , Sarcoma, Synovial/diagnostic imaging , Sarcoma, Synovial/pathology , Sarcoma, Synovial/diagnosis , Middle Aged , Male , Female
5.
J Am Soc Cytopathol ; 13(3): 213-218, 2024.
Article in English | MEDLINE | ID: mdl-38575468

ABSTRACT

INTRODUCTION: Insulinoma-associated protein 1 (INSM1) is an immunohistochemical marker commonly used to confirm cytomorphological concordant neuroendocrine tumors/carcinomas (NETs/NECs), demonstrating high utility in small samples. Previous reports have suggested comparable INSM1 staining in CytoLyt-fixed cell blocks and formalin-fixed surgical pathology specimens. This study aimed to assess INSM1 immunoreactivity using both fixation methods and investigate potential factors contributing to its variable expression. MATERIALS AND METHODS: A retrospective query was performed (03/31/21-05/31/22) for NET/NEC cases that had both formalin- and CytoLyt-fixed cell blocks. We collected clinical data and reporting of immunostains for each case. INSM1 staining was evaluated in both fixation methods, and reported as positive, negative, or equivocal. Equivocal INSM1 staining was further scored as a percentage of 1%-100% and intensity of weak (faint staining), moderate (darker staining), and strong (dense staining). RESULTS: Our search identified 20 cases from diverse body sites, including mediastinal lymph nodes (40%), pancreas (35%), lung (20%), and porta hepatis lymph nodes (5%). All cases exhibited a widespread positivity (over 90%) in formalin-fixed cell blocks. In contrast, CytoLyt fixed cells showed a negative stain in 65% of cases and 30% exhibited an equivocal positivity. CONCLUSIONS: While INSM1 is previously reported as a sensitive (75%-100%) and specific (82.7%-100%) marker for NET/NECs, our study found a reduced immunohistochemical staining in CytoLyt-fixed cell blocks. Consequently, false negative INSM1 immunohistochemical results in CytoLyt-fixed cell block material may pose a pitfall in the diagnosis of NET/NEC.


Subject(s)
Biomarkers, Tumor , Formaldehyde , Immunohistochemistry , Repressor Proteins , Tissue Fixation , Humans , Retrospective Studies , Repressor Proteins/metabolism , Biomarkers, Tumor/metabolism , Immunohistochemistry/methods , Tissue Fixation/methods , Neuroendocrine Tumors/pathology , Neuroendocrine Tumors/metabolism , Neuroendocrine Tumors/diagnosis , Female , Middle Aged , Male , Aged , Adult , Fixatives , Pancreatic Neoplasms/pathology , Pancreatic Neoplasms/metabolism , Pancreatic Neoplasms/diagnosis , Carcinoma, Neuroendocrine/pathology , Carcinoma, Neuroendocrine/diagnosis , Carcinoma, Neuroendocrine/metabolism
6.
J Neuroendocrinol ; 36(6): e13394, 2024 06.
Article in English | MEDLINE | ID: mdl-38626758

ABSTRACT

Small-cell neuroendocrine carcinomas (SCNECs) of the female genital tract are rare and aggressive tumors that are characterized by a high rate of recurrence and poor prognosis. They can arise from various sites within the female genital tract, including the cervix, endometrium, ovary, fallopian tube, vagina, and vulva. They are composed of cells with neuroendocrine features, such as the ability to produce and secrete hormones and peptides, and a high mitotic rate. Immunohistochemical staining for neuroendocrine markers, such as chromogranin A, synaptophysin, and CD56, can aid in the diagnosis of these tumors. This article provides an overview of the epidemiology, etiology, and risk factors associated with these tumors, as well as their clinical presentation, cellular characteristics, diagnosis, and finally the current treatment options for SCNECs, including surgery, chemotherapy, and radiation therapy, alone or in combination.


Subject(s)
Carcinoma, Neuroendocrine , Carcinoma, Small Cell , Genital Neoplasms, Female , Humans , Female , Carcinoma, Neuroendocrine/diagnosis , Carcinoma, Neuroendocrine/therapy , Carcinoma, Neuroendocrine/pathology , Carcinoma, Small Cell/therapy , Carcinoma, Small Cell/diagnosis , Carcinoma, Small Cell/epidemiology , Carcinoma, Small Cell/pathology , Genital Neoplasms, Female/therapy , Genital Neoplasms, Female/diagnosis , Genital Neoplasms, Female/pathology , Genital Neoplasms, Female/epidemiology , Risk Factors
7.
Front Biosci (Landmark Ed) ; 29(3): 100, 2024 Mar 13.
Article in English | MEDLINE | ID: mdl-38538277

ABSTRACT

BACKGROUND: As a dedifferentiated tumor, small cell endometrial neuroendocrine tumors (NETs) are rare and frequently diagnosed at an advanced stage with a poor prognosis. Current treatment recommendations are often extrapolated from histologically similar tumors in other sites or based on retrospective studies. The exploration for diagnostic and therapeutic markers in small cell NETs is of great significance. METHODS: In this study, we conducted single-cell RNA sequencing on a specimen obtained from a patient diagnosed with small cell endometrial neuroendocrine carcinoma (SCNEC) based on pathology. We revealed the cell map and intratumoral heterogeneity of the cancer cells through data analysis. Further, we validated the function of ISL LIM Homeobox 1 (ISL1) in vitro in an established neuroendocrine cell line. Finally, we examined the association between ISL1 and tumor staging in small cell lung cancer (SCLC) patient samples. RESULTS: We observed the significant upregulation of ISL1 expression in tumor cells that showed high expression of the neuroepithelial markers. Additionally, in vitro cell function experiments demonstrated that the high ISL1 expression group exhibited markedly higher cell proliferation and migration abilities compared to the low expression group. Finally, we showed that the expression level of ISL1 was correlated with SCLC stages. CONCLUSIONS: ISL1 protein in NETs shows promise as a potential biomarker for diagnosis and treatment.


Subject(s)
Carcinoma, Neuroendocrine , Neuroendocrine Tumors , Female , Humans , Transcription Factors/genetics , Retrospective Studies , Single-Cell Gene Expression Analysis , LIM-Homeodomain Proteins/genetics , LIM-Homeodomain Proteins/analysis , Neuroendocrine Tumors/diagnosis , Neuroendocrine Tumors/metabolism , Neuroendocrine Tumors/pathology , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Endometrium/chemistry , Endometrium/metabolism , Endometrium/pathology , Carcinoma, Neuroendocrine/diagnosis , Carcinoma, Neuroendocrine/genetics , Carcinoma, Neuroendocrine/therapy
8.
J Cancer Res Ther ; 20(1): 464-466, 2024 Jan 01.
Article in English | MEDLINE | ID: mdl-38554365

ABSTRACT

We report a case of the 46-year-old female patient, who presented with diffuse nodular liver calcifications on computed tomography. Histopathology of the calcified nodules revealed neuroendocrine tumors (NETs). Calcified NET liver metastases are extremely rare and need to be considered in the differential diagnosis with other benign and malignant liver calcification.


Subject(s)
Calcinosis , Carcinoma, Neuroendocrine , Liver Neoplasms , Neuroendocrine Tumors , Female , Humans , Middle Aged , Liver Neoplasms/diagnostic imaging , Liver Neoplasms/pathology , Carcinoma, Neuroendocrine/diagnosis , Tomography, X-Ray Computed , Neuroendocrine Tumors/diagnostic imaging , Neuroendocrine Tumors/pathology , Calcinosis/diagnostic imaging , Calcinosis/pathology
9.
Adv Anat Pathol ; 31(3): 169-177, 2024 May 01.
Article in English | MEDLINE | ID: mdl-38523484

ABSTRACT

The most common neuroendocrine tumor in the urinary bladder is small cell carcinoma, which can be pure or mixed with components of urothelial or other histologic subtypes. Large cell neuroendocrine carcinoma of the bladder is rare and remains ill-defined but is increasingly recognized. Well-differentiated neuroendocrine tumor and paraganglioma can arise in the bladder but are very rare in this location. Recent advances in molecular characterization allowed for better classification and may offer improved stratification of these tumors.


Subject(s)
Carcinoma, Neuroendocrine , Neuroendocrine Tumors , Urinary Bladder Neoplasms , Humans , Urinary Bladder Neoplasms/pathology , Carcinoma, Neuroendocrine/diagnosis , Carcinoma, Neuroendocrine/pathology , Urinary Bladder/pathology , Neuroendocrine Tumors/pathology
10.
Calcif Tissue Int ; 114(5): 550-553, 2024 May.
Article in English | MEDLINE | ID: mdl-38506956

ABSTRACT

In this case report, we describe an uncommon case of neuroendocrine cancer of unknown origin began with cauda equina syndrome in a patient affected by Paget disease of bone (PDB). A 76-year-old man with diagnosis of PDB, without history of pain or bone deformity, developed sudden severe low back pain. Bone alkaline phosphatase was increased and MRI and whole-body scintigraphy confirmed the localization of the disease at the third vertebra of the lumbar spine. Treatment with Neridronic Acid was started, but after only 2 weeks of therapy anuria and bowel occlusion occurred together with lower limb weakness and walking impairment. Cauda equina syndrome consequent to spinal stenosis at the level of L2-L3 was diagnosed after admission to Emergency Department and the patient underwent neurosurgery for spinal medulla decompression. The histologic results showed a complete subversion of bone structure in neoplastic tissue, consistent with metastatic neuroendocrine carcinoma of unknown origin. In conclusion, low back pain in the elderly may require deep investigation to individuate rare diseases. In asymptomatic patients with apparently stable PDB, the sudden appearance of pain or neurologic symptoms may alert the clinician for the possibility of other superimposing diseases, like bone metastases.


Subject(s)
Osteitis Deformans , Humans , Aged , Male , Osteitis Deformans/complications , Osteitis Deformans/diagnosis , Osteitis Deformans/pathology , Bone Neoplasms/secondary , Neuroendocrine Tumors/pathology , Neuroendocrine Tumors/complications , Neuroendocrine Tumors/secondary , Cauda Equina Syndrome/etiology , Low Back Pain/etiology , Lumbar Vertebrae/pathology , Lumbar Vertebrae/diagnostic imaging , Carcinoma, Neuroendocrine/pathology , Carcinoma, Neuroendocrine/secondary , Carcinoma, Neuroendocrine/diagnosis
11.
J Am Soc Cytopathol ; 13(3): 205-212, 2024.
Article in English | MEDLINE | ID: mdl-38433072

ABSTRACT

INTRODUCTION: Accurate grading of pancreatic neuroendocrine tumors (PanNETs) relies on the assessment of Ki-67 immunohistochemistry (IHC). While digital imaging analysis (DIA) has been employed for Ki-67 IHC assessment in surgical specimens, its applicability to cytologic specimens remains underexplored. This study aimed to evaluate an automated DIA for assessing Ki-67 IHC on PanNET cell blocks. MATERIALS AND METHODS: The study included 61 consecutive PanNETs and 5 pancreatic neuroendocrine carcinomas. Ki-67 IHC slides from cell blocks were digitally scanned into whole slide images using Philips IntelliSite Scanners and analyzed in batches using the Visiopharm Ki-67 App in a digital workflow. Ki-67 scores obtained through DIA were compared to pathologists' manual scores. RESULTS: The Pearson correlation coefficient of the percentage of Ki-67-stained nuclei between DIA reads and the originally reported reads was 0.9681. Concordance between DIA Ki-67 grades and pathologists' Ki-67 grades was observed in 92.4% (61/66) of cases with the calculated Cohen's Kappa coefficient of 0.862 (almost perfect agreement). Discordance between DIA and pathologists' consensus reads occurred in 5 PanNET cases which were upgraded from G1 to G2 by DIA due to contaminated Ki-67-stained inflammatory cells. CONCLUSIONS: DIA demonstrated excellent concordance with pathologists' assessments, with only minor grading discrepancies. However, the essential role of pathologists in confirming results is emphasized to enhance overall accuracy.


Subject(s)
Immunohistochemistry , Ki-67 Antigen , Neoplasm Grading , Neuroendocrine Tumors , Pancreatic Neoplasms , Humans , Ki-67 Antigen/metabolism , Pancreatic Neoplasms/pathology , Pancreatic Neoplasms/diagnosis , Pancreatic Neoplasms/metabolism , Immunohistochemistry/methods , Neuroendocrine Tumors/pathology , Neuroendocrine Tumors/metabolism , Neuroendocrine Tumors/diagnosis , Biomarkers, Tumor/metabolism , Biomarkers, Tumor/analysis , Image Interpretation, Computer-Assisted/methods , Female , Male , Image Processing, Computer-Assisted/methods , Middle Aged , Automation, Laboratory , Carcinoma, Neuroendocrine/pathology , Carcinoma, Neuroendocrine/diagnosis , Aged , Reproducibility of Results
16.
JNMA J Nepal Med Assoc ; 62(270): 152-154, 2024 Feb 24.
Article in English | MEDLINE | ID: mdl-38409975

ABSTRACT

Large cell neuroendocrine carcinoma of the gallbladder is an extremely rare tumour with aggressive behaviour and a bad prognosis. Here, we report a case of a 65-year-old lady suspected of carcinoma of the gallbladder and underwent extended cholecystectomy. The histopathology report revealed neuroendocrine carcinoma of a large cell type of gall bladder infiltrating the liver and three periportal and pericholedochal lymph nodes. She had an uneventful perioperative period and was doing good till 6 months of follow-up. The only potentially curative treatment for large cell neuroendocrine carcinoma of the gallbladder is aggressive surgical resection, owing to its aggressive behaviour and bad prognosis. Keywords: carcinoma; case reports; cholecystectomy; gallbladder.


Subject(s)
Carcinoma, Large Cell , Carcinoma, Neuroendocrine , Gallbladder Neoplasms , Female , Humans , Aged , Gallbladder Neoplasms/diagnosis , Gallbladder Neoplasms/surgery , Gallbladder Neoplasms/pathology , Carcinoma, Neuroendocrine/diagnosis , Carcinoma, Neuroendocrine/surgery , Carcinoma, Neuroendocrine/pathology , Cholecystectomy , Prognosis , Carcinoma, Large Cell/diagnosis , Carcinoma, Large Cell/surgery , Carcinoma, Large Cell/pathology
20.
Pathologie (Heidelb) ; 45(1): 35-41, 2024 Feb.
Article in German | MEDLINE | ID: mdl-38175232

ABSTRACT

Pancreatic neuroendocrine neoplasms (PanNEN) are rather rare entities. Morphology, combined with immunohistochemistry, allows typing and grading, thereby leading therapeutic decisions. Depending on tumor stage and differential diagnosis, a broad diagnostic panel may be required. The present work summarizes the minimal diagnostic, prognostic, and predictive markers in PanNEN.Markers of choice for defining a neuroendocrine phenotype are synaptophysin, chromogranin A, and INSM1. The proliferation fraction Ki67 is indispensable for grading, while p53 and Rb1 can help in the differentiation from neuroendocrine carcinoma (NEC). Transcription factors, such as cdx2, TTF­1, and Islet­1, can indicate the site of a primary tumor in the setting of a cancer of unknown primary (CUP). DAXX/ATRX immunohistochemistry has mainly prognostic value. Molecular pathology studies currently have little practical value in the diagnosis of PanNEN.An important pitfall in routine diagnostics is the wide spectrum of differential diagnoses mimicking neuroendocrine neoplasms. An expanded immunohistochemical panel is strongly recommended in case of doubt.


Subject(s)
Carcinoma, Neuroendocrine , Neuroendocrine Tumors , Pancreatic Neoplasms , Humans , Immunohistochemistry , Biomarkers, Tumor , Neuroendocrine Tumors/diagnosis , Carcinoma, Neuroendocrine/diagnosis , Pancreatic Neoplasms/diagnosis , Repressor Proteins
SELECTION OF CITATIONS
SEARCH DETAIL
...